SGF29 and leukemia: On the other hand, ectopic expression of the synthetic SGF29 cDNA completely reversed sgSGF29-dual–mediated anti-leukemia phenotypes (Fig. 3, B to D; green group), providing proof-of-concept evidence of targeting SGF29 in vivo to disrupt the progression/maintenance of human leukemia.